Domain-specific large language model for predicting prostate cancer treatment plan.

U Umar Ghaffar (Mayo Clinic in Arizona, Phoenix, AZ) A Amara Tariq (Mayo Clinic in Arizona, Phoenix) M Mouneeb Choudry (Mayo Clinic in Arizona, Phoenix, AZ) L Logan Briggs (Mayo Clinic in Arizona, Phoenix, AZ) A Aneeta Channar (Rutgers-Jersey City Medical Center RWJBarnabas Health, Jersey City, NJ) I Imon Banerjee (Mayo Clinic Arizona, Phoenix, AZ) M Man Luo I Irbaz Bin Riaz (Irbaz Bin Riaz, MD, PhD; R. Bryan Rumble, MSc; Thomas A. Hope, MD; Giuseppe Procopio, MD; and Neha Vapiwala, MD; Mayo Clinic, Phoenix, AZ; American Society of Clinical Oncology, Alexandria, VA; University of California, San Francisco, San Francisco, CA; Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy; and University of Pennsylvania Abramson Cancer Center, Philadelphia, PA) H Haidar Abdul-Muhsin (Mayo Clinic Arizona, Phoenix, AZ)

Abstract

428 Background: Prostate cancer management presents a significant healthcare burden, with the need to efficiently triage patients for treatment. Our objective is to leverage large language models to predict physician-recommended treatment plans from unstructured clinical notes. By accurately predicting treatment plans, we aim to risk stratify and triage patients effectively, thereby optimizing the allocation of physician resources. Methods: 448 unstructured initial urology consultation patient notes following first positive prostate cancer biopsy were identified. The recommended and final treatments received were manually annotated to establish ground truth labels (Table 1). The dataset was split 80:20 for training and testing, preprocessed to remove plan sections and formatted into question-answer (QA) format. A domain-specific large language model (LLM) inspired by GPT and a specialized tokenizer (PCa- LLM) for prostate cancer terminology were developed. QA models were built using the PCa-LLM and compared with those using GPT-2 as the backbone to predict recommended and final treatments. Results: For the physician-recommended treatment plans, our LLM (PCa-LLM) showed superior performance with higher AUROC scores for curative vs. non-curative treatments (0.78 vs. 0.65), chemo-hormonal vs. other non-curative treatments (0.89 vs. 0.65), and surveillance vs. all other treatments (0.72 vs. 0.70), while both models achieved the same high AUROC of 0.99 for chemo-hormonal vs. all other treatments. For final treatments, PCa-LLM demonstrated better AUROC for curative vs. non-curative treatments (0.77 vs. 0.74) and chemo-hormonal vs. other non-curative treatments (0.71 vs. 0.66), while GPT2 outperformed PCa-LLM for surveillance vs. all other treatments (0.78 vs. 0.70). Both models achieved an AUROC of 0.99 for chemo-hormonal vs. all other treatments. Conclusions: PCa-LLM accurately predicted most treatment categories better than GPT2, with higher AUROC scores, and can be utilized to triage prostate cancer patients using initial consultation notes. Task Physician -Recommended Treatment Plan Final Treatment Received Curative Prostatectomy/Radiation 228 230 Non-Curative Focal Therapy 22 15 Active Surveillance 40 45 Chemo-hormonal 30 30 Model Predictions (AUROC) GPT2 PCa-LLM GPT2 PCa-LLM Curative vs. non-curative 0.65 0.78 0.74 0.77 Chemohormonal vs. other non-curative 0.65 0.89 0.66 0.71 Chemohormonal vs. all other 0.99 0.99 0.99 0.99 Surveillance vs. other non-curative 0.64 0.60 0.67 0.59 Surveillance vs. all other 0.70 0.72 0.78 0.70

Article Details

Volume / Issue Vol. 43, Issue 5_suppl
Published February 10, 2025
Pages 428-428
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (9)

U

Umar Ghaffar

Mayo Clinic in Arizona, Phoenix, AZ

A

Amara Tariq

Mayo Clinic in Arizona, Phoenix

M

Mouneeb Choudry

Mayo Clinic in Arizona, Phoenix, AZ

L

Logan Briggs

Mayo Clinic in Arizona, Phoenix, AZ

A

Aneeta Channar

Rutgers-Jersey City Medical Center RWJBarnabas Health, Jersey City, NJ

I

Imon Banerjee

Mayo Clinic Arizona, Phoenix, AZ

M

Man Luo

I

Irbaz Bin Riaz

Irbaz Bin Riaz, MD, PhD; R. Bryan Rumble, MSc; Thomas A. Hope, MD; Giuseppe Procopio, MD; and Neha Vapiwala, MD; Mayo Clinic, Phoenix, AZ; American Society of Clinical Oncology, Alexandria, VA; University of California, San Francisco, San Francisco, CA; Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy; and University of Pennsylvania Abramson Cancer Center, Philadelphia, PA

H

Haidar Abdul-Muhsin

Mayo Clinic Arizona, Phoenix, AZ